Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
AbstractBackground:. Computational pathology has successfully incorporated artificial intelligence (AI) methodologies for various applications, including the predictions of therapeutic response, ...
Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, ...
Abstract. KSQ-001EX is an engineered TIL (eTIL) therapy with CRISPR/Cas9-mediated inactivation of SOCS1, a negative regulator of cytokine signaling and T cell function. SOCS1 was identified in a ...
AbstractBackground:. DS-8201a is a HER2-targeting antibody drug conjugate with a topoisomerase 1 (topo1) inhibitor payload. Preclinical evidence suggests that inhibiting PARP can potentiate topo1 ...
SciBrunch Therapeutics Co., Ltd, Shanghai, China.
Cancer Res (2026) 86 (7_Supplement): 5810.
Abstract. PD-L1 is an established immunotherapy target highly expressed in various solid tumors, while B7-H3 is another extensively investigated target overexpressed on a wide range of tumor cells.
Abstract. CEACAM5 and CDH17 are preferentially expressed in gastrointestinal tumors, including more than 95% of colorectal cancers, 80% of gastric and pancreatic cancers, and 70% of ...
Abstract. Following peak tobacco incidence in the mid-1980’s there has been a large reduction in lung cancer incidence among men that has not been seen among women. Lung cancer at a young age is now ...
DCx Biotherapeutics, Saint-Laurent, Quebec, Canada.
You do not currently have access to this content.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results